Literature DB >> 32828387

Evidence-Based Dose Planning Aims and Dose Prescription in Image-Guided Brachytherapy Combined With Radiochemotherapy in Locally Advanced Cervical Cancer.

Kari Tanderup1, Nicole Nesvacil2, Kathrin Kirchheiner2, Monica Serban3, Sofia Spampinato4, Nina Boje Kibsgaard Jensen4, Maximilian Schmid2, Stephanie Smet5, Henrike Westerveld6, Stefan Ecker2, Umesh Mahantshetty7, Jamema Swamidas8, Supriya Chopra8, Remi Nout9, Li Tee Tan10, Lars Fokdal4, Alina Sturdza2, Ina Jürgenliemk-Schulz9, Astrid de Leeuw11, Jacob Christian Lindegaard4, Christian Kirisits2, Richard Pötter2.   

Abstract

The last 2 decades have witnessed the development and broad adoption of image-guided adaptive brachytherapy (IGABT) combined with radiochemotherapy in patients with locally advanced cervical cancer. A variety of brachytherapy techniques and dose/fractionation schedules have been applied, and until recently, there was no strong evidence available for preferring one approach to another. However, large volumes of data have now provided high level clinical evidence for dose-effect relations for both disease and morbidity endpoints. It is therefore now possible to apply evidence based dose planning aims and dose prescription protocols in IGABT for locally advanced cervical cancer. This review gives an overview of targets/organs-at-risk and disease/morbidity endpoints which are relevant in the context of treatment planning and dose prescription in IGABT. The dosimetric and clinical evidence is summarized to support the implementation of dose prescription protocols which include hard and soft constraints for targets and organs at risk.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Year:  2020        PMID: 32828387     DOI: 10.1016/j.semradonc.2020.05.008

Source DB:  PubMed          Journal:  Semin Radiat Oncol        ISSN: 1053-4296            Impact factor:   5.934


  5 in total

1.  Dosimetric impact of target definition in brachytherapy for cervical cancer - Computed tomography and trans rectal ultrasound versus magnetic resonance imaging.

Authors:  Jamema Swamidas; Jeevanshu Jain; Nicole Nesvacil; Kari Tanderup; Christian Kirisits; Max Schmid; Priyanka Agarwal; Kishore Joshi; Pushpa Naga; Chira Ranjan Khadanga; Shivakumar Gudi; Lavanya Gurram; Supriya Chopra; Umesh Mahantshetty
Journal:  Phys Imaging Radiat Oncol       Date:  2022-03-04

2.  Japanese Society for Radiation Oncology Consensus Guidelines of combined intracavitary and interstitial brachytherapy for gynecological cancers.

Authors:  Naoya Murakami; Tatsuya Ohno; Takafumi Toita; Ken Ando; Noriko Ii; Hiroyuki Okamoto; Toru Kojima; Kayoko Tsujino; Koji Masui; Ken Yoshida; Hitoshi Ikushima
Journal:  J Radiat Res       Date:  2022-05-18       Impact factor: 2.724

3.  Clinical Efficacy of Image-Guided Radiation Therapy for Cervical Cancer and Its Impact on Patients' Serum Tumor Markers and KPS Scores.

Authors:  Xin You; Feng-Yan Hou
Journal:  J Oncol       Date:  2022-07-13       Impact factor: 4.501

Review 4.  A Review of PRESAGE Radiochromic Polymer and the Compositions for Application in Radiotherapy Dosimetry.

Authors:  Muhammad Zamir Mohyedin; Hafiz Mohd Zin; Mohd Zulfadli Adenan; Ahmad Taufek Abdul Rahman
Journal:  Polymers (Basel)       Date:  2022-07-16       Impact factor: 4.967

5.  Prognostic factors for IB2-IIIB cervical cancer patients treated by radiation therapy with high-dose-rate brachytherapy in a single-institution study.

Authors:  Yu-Ting Xiu; Fan-Xu Meng; Zhuo Wang; Kang-Kang Zhao; Yun-Long Wang; Zhi-Shen Chen; Bao-Sheng Sun
Journal:  J Contemp Brachytherapy       Date:  2022-08-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.